Clofarabine

• Description:

  Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H300

• Target:

  Apoptosis; Autophagy; Nucleoside Antimetabolite/Analog

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Metabolic Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/clofarabine.html

• Purity:

  99.88

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O[C@H]1[C@H](F)[C@H](N(C=N2)C3=C2C(N)=NC(Cl)=N3)O[C@@H]1CO

• Molecular Formula:

  C10H11ClFN5O3

• Molecular Weight:

  303.68

• Precautions:

  H300

• References & Citations:

  [1]Peter L Bonate, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006 Oct;5 (10) :855-63.|[2]Hai-Bo Liu, et al. [Effect of clofarabine on proliferation and Bcl-2 expression of NB4 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20 (3) :571-3.|[3]Jia-Jie Luan, et al. Dosing-time contributes to chronotoxicity of clofarabine in mice via means other than pharmacokinetics. Kaohsiung J Med Sci. 2016 May;32 (5) :227-34.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  123318-82-1